Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

November 25, 2024 10:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / November 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on December 3, 2024 at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, and present virtually on December 5, 2024 at the Emerging Growth Conference.Participation Instructions for Jaguar Health's In-Person Presentation at...

Read more

Neurotech Innovator UNEEG Medical Receives FDA Breakthrough Device Designation Within Monitoring and Diagnostic of Epilepsy

November 25, 2024 9:00 AM

The designation is a result of UNEEG's strong focus on developing novel disease management support tools with transformational and first-to-market potentialTo qualify for Breakthrough Device Designation from the US Food and Drug Administration (FDA), a device technology must address an unmet need and provide evidence that it has the potential to provide for more effective treatment of patients - or as stated, "substantial clinical...

Read more

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

November 25, 2024 9:00 AM

Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed for human pilot study #3 (the "Study") investigating a DehydraTECH-processed version of the dual action glucagon-like peptide-1 ("GLP-1") + glucose-dependent insulinotropic peptide ("GIP") receptor agonist tirzepatide (sold commercially as Zepbound®) in an oral dose...

Read more

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

November 25, 2024 9:00 AM

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in...

Read more

S4 Medical Receives FDA 510(k) Approval for its Redesigned Esophageal Deviation Device and Begins Commercialization

November 25, 2024 7:35 AM

S4 Medical Corp, an Ohio based company committed to making atrial fibrillation (AF) ablation procedures safer, has received 510(k) approval by the U.S. FDA for its redesigned esolution® esophageal deviation device. S4 Medical now has the first and only FDA approved device to prevent ablation-related esophageal injury in all ablation modalities. Following receipt of the FDA's De Novo approval last year, S4 Medical engaged in a product...

Read more

Acreage Provides Update on Corporate Transactions

November 25, 2024 7:30 AM

Acreage Holdings, Inc. ("Acreage" or the "Company") (CSE:ACRG.A.U, ACRG.B.U)(OTCQX:ACRHF, ACRDF), a vertically integrated, multi-state operator of cannabis cultivation and retailing facilities in the U.S., is pleased to announce that, further to its press releases of June 4 and June 5, 2024, Acreage anticipates that Canopy USA, LLC ("Canopy USA") will complete its acquisition of Acreage pursuant to the Acquisitions (as defined below) in...

Read more

Moderna to Present at Upcoming Conferences in December 2024

November 25, 2024 7:00 AM

CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ETPiper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ETA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors...

Read more

Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

November 25, 2024 7:00 AM

Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (Nasdaq:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have...

Read more

BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity

November 25, 2024 3:05 AM

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce the expansion of its next-generation product pipeline. This includes proprietary Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet) drug delivery systems targeting autoimmune diseases such as Multiple sclerosis ("MS"), Myasthenia gravis ("MG"), Lupus nephritis ("LN"), and Rheumatoid arthritis ("RA"), as...

Read more

Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program

November 22, 2024 3:30 PM

MALMÖ, SWEDEN / ACCESSWIRE / November 22, 2024 / Ascelia Pharma (STO:ACE) The board of directors of Ascelia Pharma AB ("Ascelia Pharma") has on 22 November 2024 resolved to convert 26,310 series C shares into ordinary shares for delivery of shares to participants in the long-term incentive program in the form of a performance-based share saving program that was adopted at the annual general meeting held on 5 May 2021 ("LTI 2021").The board of...

Read more

Jacqueline Schaffer Featured in Exclusive Online Interview Highlighting Her Journey of Compassion, Wellness, and Entrepreneurship

November 22, 2024 2:30 PM

LOS ANGELES, CA / ACCESSWIRE / November 22, 2024 / Jacqueline Schaffer, a successful beauty business owner, medical doctor, and philanthropist, is featured in an exclusive interview that delves into her inspiring entrepreneurial journey. As the founder of Schique Skincare, a vegan and plant-based skincare line, Schaffer shares her motivations, challenges, and unwavering commitment to both wellness and ethical beauty.In the interview, Jacqueline...

Read more

Laurel Bridge Software Advances Medical Imaging Workflow With New AI and Cloud Innovations at RSNA 2024

November 22, 2024 9:00 AM

NEWARK, DE / ACCESSWIRE / November 22, 2024 / Laurel Bridge Software, a leader in medical imaging workflow solutions, is excited to showcase its latest advancements in workflow technology at RSNA 2024. As AI adoption in healthcare skyrockets, the demand for solutions that deliver seamless AI workflow is growing. Moreover, cloud-hosted models are becoming increasingly popular, requiring healthcare organizations to accelerate their shift to the...

Read more

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

November 22, 2024 9:00 AM

DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year."We are honored to be recognized...

Read more

Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting

November 22, 2024 8:45 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group focused on developing new therapies for blood diseases announces that it has posted, or otherwise made available, a circular to shareholders containing a notice convening an Extraordinary General Meeting to be held at 10.00 a.m. on 9 December 2024 at 1 Heddon Street, London W1B 4BD.The Company is seeking the approval of shareholders by way of an ordinary resolution to execute...

Read more

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

November 22, 2024 8:45 AM

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the U.S.NP300 is a novel antisecretory drug with a similar...

Read more

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

November 22, 2024 8:35 AM

SEATTLE, WA / ACCESSWIRE / November 22, 2024 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, provided additional details about its robust oncology pipeline which is poised to potentially address some of the most challenging and aggressive forms of cancer in both blood and solid tumors. As bispecific antibodies gain prominence for their revolutionary therapeutic potential and...

Read more

Frequency Exchange Welcomes Former NHL Star and Current President of the Boston Bruins Cam Neely to Its Advisory Board

November 22, 2024 8:00 AM

VANCOUVER, BC / ACCESSWIRE / November 22, 2024 / Frequency Exchange Corp. ("Frequency Exchange" or the "Company") (TSXV:FREQ)(OTC PINK:FRECF) is pleased to announce former NHL star, Hockey Hall of Fame Inductee and President of the Boston Bruins Cam Neely will be joining its Advisory Board, to play a strategic role as the Company enters its next phase of growth.Mr. Neely was a power forward for the Vancouver Canucks and Boston Bruins from...

Read more

Sunshine Biopharma Launches a New Generic Prescription Drug

November 22, 2024 8:00 AM

FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched a new generic prescription drug.The newly launched drug is Ursodiol, a generic version of URSO DS®. Ursodiol,...

Read more

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

November 22, 2024 7:30 AM

NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference taking place December 3-5, 2024 in Coral Gables, Florida. The Company will also participate in one-on-one meetings.7th Annual Evercore ISI HealthCONx Conference -...

Read more

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

November 22, 2024 2:00 AM

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company developing innovative therapies and treatments for blood diseases, is pleased to announce that the Institutional Review Board (IRB)of the Company's first clinical site has granted approval to initiate a Phase I clinical trial of the...

Read more